Compugen (NASDAQ:CGEN - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of $0.07 per share and revenue of $17.47 million for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.
Compugen Trading Up 3.8 %
Shares of NASDAQ CGEN traded up $0.07 during midday trading on Friday, reaching $1.92. 204,525 shares of the company were exchanged, compared to its average volume of 852,352. The stock has a fifty day simple moving average of $2.03 and a 200 day simple moving average of $1.83. The stock has a market cap of $171.34 million, a P/E ratio of 96.00 and a beta of 2.65. Compugen has a 1 year low of $1.35 and a 1 year high of $3.03.
Analyst Upgrades and Downgrades
Separately, Oppenheimer started coverage on Compugen in a report on Monday, January 13th. They issued an "outperform" rating and a $4.00 target price on the stock.
Read Our Latest Research Report on CGEN
About Compugen
(
Get Free Report)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Further Reading
Before you consider Compugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compugen wasn't on the list.
While Compugen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
